Introduction
Improved physical targeting of radiation has enabled more precise dose delivery to the tumor volume, while limiting exposure to surrounding normal tissues. Nevertheless, the treatment of certain malignancies remains problematic, including the many solid tumors where local control is the predominant issue, such as the brain, prostate, cervix and head and neck. [1] [2] [3] [4] Resistance is in part due to the irregular patterns of cancer cell proliferation that often lead to abnormal vascular growth and characteristic regions of hypoxia. 5 Hypoxic areas, observed in numerous human tumors, 4, 6, 7 have been shown to adversely affect locoregional control and/or disease-free survival after surgery, radiotherapy and chemotherapy. [8] [9] [10] Hypoxia not only provides an environment directly facilitating chemo-and radio-resistance but also encourages the evolution of phenotypic changes inducing permanent resistance to treatment. 11 Therefore, successful treatment of hypoxic cells should not only improve local control but also impact on overall patient survival.
Although a significant adverse factor for cancer prognosis, severe hypoxia does not occur in normal tissues and thus can be exploited for selective cancer treatment. 12 Hypoxia induces the overexpression of a number of genes, in the majority of cases by the binding of the transcription factor hypoxia-inducible factor (HIF) to hypoxia-responsive elements (HREs) within the gene promoters. 13, 14 Native and chimeric HRE-containing promoters have been successfully used to drive experimental gene therapy under hypoxic conditions in vitro and in vivo. [15] [16] [17] In order to combine hypoxia-mediated gene therapy with radiotherapy and to maximize the activation of the vectors within the tumor mass, we have shown that gene enhancers consisting of HREs and radiation-responsive CArG elements from the early growth response (Egr) 1 gene are activated by either hypoxia, radiation, or the combined stimuli. 17 A promoter comprising of five HREs from the erythropoietin (Epo) gene and nine CArG elements (denoted Epo/E9) produced the most selective and robust initiation of gene expression, across all treatments and tumor cell types, and could effectively drive experimental suicide gene therapy in vitro. 17 Inducible promoters offer the potential to selectively control therapeutic gene expression in the tumor while minimizing normal tissue toxicity. Nevertheless, when activated, these promoters often result in lower activity compared with strong constitutive promoters, and transgene expression is limited to the period of stimulation, returning to basal levels following withdrawal of the induction trigger. We have devised a 'molecular switch' vector system based on Cre/loxP recombination, which allows long-term, high-level expression following activation by a specific stimulus. 18 In this system, a primary inducible promoter controls the expression of Cre recombinase (derived from bacteriophage P1), which in turn recognizes specific DNA sequences (loxP sites), causing intramolecular recombination. Unidirectional loxP sites flank (or 'flox') a transcriptional silencing 'Stop' cassette that prevents expression of a transgene from an upstream constitutive secondary promoter. 18 Using our early radiation-responsive dual plasmid system, a 3 Gy dose induced a 40-fold increase in radiation-activated green fluorescent protein (GFP) gene expression, compared with two to three-fold when the reporter was controlled directly by the same promoter. 18 In the present study, we describe for the first time the engineering of all the components of our molecular switch into single vectors containing novel HRE and CArG-based chimeric promoters inducible by hypoxia and/or radiation. For tumor cell killing, the herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) combination was adopted as a model suicide gene system.
Results

Expression and activity of Cre recombinase in human cells
In order for Cre to catalyze loxP site-specific recombination during activation of the gene therapy switch, it needs to be located in the cell nucleus alongside the vector. Immunohistochemistry showed that Cre was localized in the nucleus following transfection of tumor cells with the pCMVCre plasmid (Table 1) , where Cre expression was under the control of the cytomegalovirus immediate-early (CMV IE) promoter (data not shown). To assess whether the molecular switch mechanism could function under hypoxic conditions, we investigated if Cre activity was affected by different oxygen concentrations (0-5% O 2 ). U87-MG glioma and MCF-7 breast adenocarcinoma cells were cotransfected with two plasmids: pCMVCre and the target plasmid pCMVStopGFP. 18 The efficiency of Cre/loxP-mediated excision of the Stop cassette was assessed as relative GFP fluorescence following 8 h exposure to different oxygen concentrations. The results revealed that Cre activity was not reduced by lowering the oxygen levels from 5 to 0.5% O 2 or even removing oxygen altogether ( Figure 1) .
Construction of the molecular switch vectors
In order to amplify levels of transgene expression induced by hypoxia and/or radiation, we have designed and produced an innovative single vector molecular switch (Figure 2 ). This is based on a two-step scheme whereby a primary inducible promoter directly controls the expression of Cre recombinase. Once synthesized, this enzyme excises the 'floxed' Stop cassette, allowing expression of HSVtk from the strong, constitutive secondary CMV IE promoter within the same plasmid ( Figure 2 ). Three primary promoters have been tested, containing either five directly repeated HREs from the human Epo gene, nine directly repeated CArG elements (E9) from the radiation-responsive Egr1 gene, or the combination of five HREs directly upstream of E9 (Epo/ E9). The constructs were named pEpoCreStoptk, pE9-CreStoptk and pEpo/E9CreStoptk, respectively (Table 1) .
To demonstrate that transgene expression resulting from molecular switch activation was indeed due to Cremediated excision of Stop, we utilized a PCR assay to monitor removal of this stuffer fragment. Two oligonucleotide primers were designed to target sequences adjacent to, and directed towards, the loxP sites within the Stop cassette (P1 and P2; Figure 3a) . After Cremediated recombination, two plasmids are formed: the therapeutic plasmid, containing HSVtk under the control of the CMV IE promoter, and the recircularized Stop cassette. When the Stop cassette circularizes, the primers' binding sites, which are now facing, are juxtaposed, with a B400 nucleotide region between them. PCR amplification indeed revealed a 450 fragment, as shown in Figure  3b (lane 2). In contrast, when Cre is not present, the Stop cassette is not excised from the switch vector. The B8 kbp region between the primers binding sites is too large for standard PCR amplification, and no PCR product is produced (Figure 3b, lane 3) .
Molecular switch enhancement of HSVtk/GCV suicide gene therapy in vitro
The selectivity and efficacy of the molecular switch system for suicide gene therapy were tested in U87-MG Hypoxia-and radiation-activated switch vectors O Greco et al cells. Cell monolayers were transiently transfected (at 10-20% efficiency) with the hypoxia-and/or radiationresponsive switch vectors, and tumor cell kill was measured after promoter activation and incubation with the prodrug GCV. As shown in Figure 4 , each stimulus activated its corresponding promoter, with some crossreactivity. In particular, CArG promoters showed some activation after hypoxia, as observed previously. 17 Cells transfected with the Epo/E9 switch vector (pEpo/ E9CreStoptk), when incubated with the prodrug GCV, after independent (or combined) stimulation showed levels of cell kill that were significantly higher than those observed in the absence of trigger stimulus or in the GFP control group (Po0.0001). Hypoxia-and radiation-activated switch vectors O Greco et al Po0.0001), which was significantly different than what observed in the identically treated GFP group (19%; Po0.0001). The efficacy of the molecular switch vectors was higher than that of the corresponding promoters controlling HSVtk directly (pE9tk, pEpotk and pEpo/ E9tk; Po0.01) and at least as high as that of the strong CMV IE promoter (pCMVtk). Importantly, the unstimulated activity of the Epo/E9 chimeric promoter was significantly reduced in the switch context (Po0.01), which should play a key role in minimizing unsolicited expression and any associated toxicity in normal tissue. Similar results were also observed in U373-MG and MCF-7 cells (data not shown).
Kinetics of Cre and HSVtk expression
As shown above and in previous studies, 17 synthetic gene promoters containing the Epo/E9 enhancer are activated by very low oxygen levels (0-0.1% O 2 ). We have now studied the inducibility of the same hypoxiaand radiation-responsive promoter using a range of Hypoxia-and radiation-activated switch vectors O Greco et al oxygen concentrations reflective of levels seen in solid tumors (0-1%). In U87-MG and MCF-7 cells, the Epo/E9 promoter was activated under all hypoxic conditions tested, with 0.5% O 2 producing the highest induction (up to 90% activity of the full CMV IE promoter; data not shown). An examination of the kinetics of Cre and HSVtk production from the pEpo/E9CreStoptk switch vector was then conducted. A stable cell line of U87-MG cells transfected with the pEpo/E9CreStoptk plasmid was established. The cell line was grown for 24 h under 0.5% O 2 (to maximize HRE induction) and Cre production was monitored by immunostaining of samples at various time intervals. Cre was detectable as early as 2 h after hypoxic exposure, increasing for 24 h (data not shown). Cells were then removed from hypoxia, given a single 3 Gy photon dose, and then returned to a 5% O 2 incubator. Cre monitoring continued, and showed negligible change over the next 24 h (Figure 5a) . A similar pattern was seen for switch-mediated HSVtk expression. Maximum HSVtk production was observed immediately after combined stimulation, with about 93% of the stable population presenting a switching event. HSVtk protein levels were maintained even 52 h poststimulus (Figure 5b ). The slight decrease in HSVtk levels observed 24 h after irradiation was not significantly different within the data group. Sham-treated (neither hypoxia-nor radiation-exposed) pEpo/E9CreStoptk cells revealed negligible levels of Cre and HSVtk throughout the same time course ( Figure 5 ).
Molecular switch enhancement of
Immunostaining of the cell lines, followed by FACS analysis, showed that 80% of the pCMVtk cell population expressed HSVtk. Analogously, 50% of the pEpo/E9tk cells expressed HSVtk after a combined stimuli of 24 h hypoxia (0.5% O 2 ) followed by 3 Gy photons. Analysis of in vitro growth rate and plating efficiency of the parental U87-MG line and the four derived lines showed no significant differences resulting from the genomic incorporation of the plasmid DNA (data not shown). The cells were injected subcutaneously (s.c.) in nude mice to establish small tumors. Untreated tumors derived from the four stable cell lines showed comparable tumorigenicity and growth rate to each other (data not shown). Mice were separated into two treatment arms, one sham-irradiated and one irradiated. Figure 6a shows the survival of sham-irradiated mice. As expected, after GCV treatment, the non-HSVtk-containing negative control tumors grew most rapidly (Figure 6a) , at a similar rate to non-GCV-treated tumors (data not shown). The GFP tumors doubled their initial geometric mean diameter (GMD) within 30 days, and by day 34 all these tumors reached a GMD of 13 mm and thus the mice were killed. In contrast, sham-irradiated pEpo/ E9CreStoptk tumors exhibited a growth delay (174 days) significantly different from that seen for the GFP tumors (Po0.001), and comparable with that seen for the pCMVtk tumors (143 days). As predicted from the in vitro studies, the 'direct' promoter vector (pEpo/E9tk) tumors also revealed some growth inhibition (86 days), although not as marked as in the pEpo/E9CreStoptk and pCMVtk groups. Importantly, complete tumor regression responses ('cures') were noted in some of the mice, which remained tumor-free at the end of the 201-day experiment (Figure 6a ). The pattern of cures mimicked the tumor growth delays seen. Among the pEpo/ E9CreStoptk tumors, 71% were cured, compared with a 60% for pCMVtk tumors, with no cures in the pEpo/ E9CreStopGFP control group. In the pEpo/E9tk tumor group, 20% of the mice were cured. In a repeat experiment, the cure rate observed in the pEpo/ E9CreStoptk group was reproduced (data not shown).
The experiment also tested the effect of combining gene therapy with radiation (Figure 6b) . Some of the mice bearing s.c. tumor xenografts not only received GCV, but were also given a single 3 Gy dose selectively to However, in the HSVtk-containing tumors, the gene therapy dominated over the effect of radiation ( Figure 6 ), with no significant difference in growth delay between irradiated and sham-irradiated tumors (irradiated pCMVtk tumors: 98 days; pEpo/E9CreStoptk: 155 days; pEpo/E9tk: 136 days). The finding that radiation did not affect overall tumor growth in pEpo/E9CreStoptk tumors indicates that maximum efficiency of transgene expression, molecular switching and prodrug activation may have been reached in this established cell line tumor xenograft system after promoter induction by endogenous tumor hypoxia. Indeed, when tumor xenograft samples from all the different treatment groups were assayed for hypoxic markers extensive areas of pimonidazole staining and HIF protein expression were revealed ( Figure 7) . Moreover, extensive production of the independent endogenous hypoxic marker carbonic anhydrase (CA)-9 was also detected in the tumor xenografts (data not shown). Finally, no damage was observed in the normal tissue and necrosis was confined to the tumor mass. Figure 6 Antitumor efficacy of the molecular switch vector for suicide gene therapy in tumor xenografts. Tumor xenografts derived from stably transfected U87-MG were given either GCV only (a) or GCV and 3 Gy X-rays (b). Animals were killed, and scored as an event, when the tumor reached a GMD of 13 mm. Otherwise they were deemed to be 'survivors' at the end of the experimental period (201 days). Kaplan-Meier survival curves were constructed for each group of mice. GCV only: pEpo/E9CreStoptk, n ¼ 7; pCMVtk, n ¼ 10; pEpo/E9tk, n ¼ 5; pEpo/E9CreStopGFP, n ¼ 4. GCV+radiation: pEpo/E9CreStoptk, n ¼ 6; pCMVtk, n ¼ 7; pEpo/E9tk, n ¼ 6; pEpo/E9CreStopGFP, n ¼ 5. Hypoxia-and radiation-activated switch vectors O Greco et al via radiation-responsive gene promoters. As precision radiation treatment is still used to treat the majority of solid tumors, this approach has inherently safe and effective tumor-specificity of transgene expression builtin, and has the potential for widespread use in different types of solid malignancies. Moreover, the additional incorporation of hypoxia-responsive promoters to trigger the gene therapy would exploit the unique physiology of many tumors, while targeting precisely the cell population refractive to therapy.
The data presented here indicate that hypoxia-and radiation-activated suicide gene therapy may be an effective means to target tumors that are resistant to conventional treatment, such as glioma. Furthermore, the use of an expression amplification system based on Cre/ loxP recombination results in enhanced efficacy of this approach, by transferring therapeutic gene activation from a tumor-selective, inducible promoter containing HREs and CArG elements, to a strong, constitutive promoter. To our knowledge, this molecular switch construct is the only Cre/loxP-based single vector system that has been produced for suicide gene therapy.
Kaczmarczyk and Green
19 developed a single plasmid system in which the androgen-inducible probasin promoter controlled the expression of Cre to activate a luciferase reporter cassette positioned in cis. The signal amplification was at least as high as that observed with the two separate plasmids in trans, although significant transgene expression was reported in the absence of specific promoter activation. 19 With our molecular switch, negligible reporter or therapeutic gene expression was detected in the absence of Cre production ( Figures 1, 4 and 5) , indicating that the Stop 'stuffer' cassette efficiently silences the CMV IE promoter. Moreover, the kinetics data demonstrate that the switch mechanism is executed rapidly after exposure to the specific stimuli in the majority of the plasmid targets. Suicide gene expression was maximum immediately after radiation and continued for at least 2 days after vector activation, even following stimulus withdrawal. These results also suggest that it would be an advantage to ensure that sufficient GCV prodrug is available from the onset of gene therapy treatment when conducting therapeutic studies. The molecular switch system was able to drive efficient and selective killing of tumor cells in vitro, even in extreme hypoxic conditions, and to effectively control tumor growth in vivo. The hypoxia-and radiationresponsive molecular switch mediated an antitumor effect as strong as the CMV IE construct, a 'gold standard' for robust transgene expression in gene therapy. Complete tumor responses were also observed, with 71% of the mice in the GCV-treated pEpo/ E9CreStoptk group having no discernible tumors at the end of the experiment. In contrast to in vitro, in vivo hypoxia appeared to be the main trigger to transgene expression (Figures 4 and 6) . Tumor xenograft samples from all the different treatment groups revealed areas of hypoxia and hypoxia-inducible proteins, while a single 3 Gy dose did not appear to improve the effectiveness of the HSVtk/GCV gene therapy. A number of factors may be involved. Direct cytotoxic effects of radiation were noted in our xenograft model, since a small, but significant, growth delay was observed in the irradiated GFP control group. However, the promoter activating potential of this single radiation dose was superseded by the strong transcription initiation induced by the extensive intratumoral hypoxia, a potent independent stimulus of gene regulation. 12 In culture, on the other hand, cells were exposed to hypoxia for only 24 h, followed by radiation. Unsurprisingly, the long-term hypoxia exposure in vivo (Figure 7 ) is likely to have contributed to vector activation to a greater extent than the single radiation treatment, leading to high levels of Stop excision, HSVtk expression and induction of tumor cell killing. This efficient vector activation is also suggested by the fact that both tumor growth inhibition and cure rate between pEpo/E9CreStoptk and pCMVtk tumors were very similar, since the 'gold standard' CMV IE promoter indicates the maximum efficacy achievable by this system. Nevertheless, after radiation, an increase in regrowth delay was observed in the pEpo/E9tk group, indicating that radio-activation of the HRE/CArG enhancer did occur and is able to contribute to gene therapy efficacy in vivo. It is therefore rational to aim to improve the trigger response by repeating the radiation dosing. Indeed, we have shown that fractionated irradiation can increase the activity of the radiationresponsive CArG components of the chimeric promoters in earlier in vivo reporter gene. Furthermore, in another study by Salloum et al. 20 using WIDR human colon carcinoma cells transfected with five Epo HREs upstream of the full Egr1 promoter and the tumoricidal cytokine tumor necrosis factor (TNF) a gene, four daily 5 Gy fractions were utilized in order for significant levels of TNFa to be detected.
HSVtk/GCV is one of the best studied suicide combinations for gene therapy. However, one of the main drawbacks of this system is that the highly charged GCV triphosphate is insoluble in lipid membranes. This impairs the diffusion of the drug and makes expression of gap junctions necessary for bystander killing. 21 Nevertheless, preclinical studies showed that tumor regression could be achieved when only 10% of the tumor cells expressed HSVtk. 22 A major role in the bystander killing observed in vivo appears to be played by the host immune system. HSVtk/GCV treatment resulted in infiltration of CD4 + and CD8 + T cells and macrophages, as well as increased production of IL-2, IL-12, IFN-g, TNF-a and granulocyte/macrophage colonystimulating factor, suggesting that the induced cell killing creates a cytokine-rich immunostimulatory environment. 23, 24 The U87-MG cell line used in the present study has been shown to express gap junctions, 25 and a bystander effect was observed in our in vitro experiments, where only 10-20% of the cells were transiently transfected (Figure 4) . However, the bystander effect should not be a prominent issue in the in vivo study, as the tumor xenografts were established from the stable cell lines, characterized in vitro by immunohistochemistry, containing a high percentage of vector-modified cells. Furthermore, immunostaining of tumor sections showed areas of hypoxia (and hypoxia-inducible genes) throughout the tumor. This indicates that in the system adopted for the in vivo experiments hypoxia-mediated activation of the switching event was likely to have occurred in the majority of the cells, leading to the results observed. Specificity of the activation was confirmed by the absence of normal tissue damage and the presence of necrosis only within the tumor mass.
Hypoxia-and radiation-activated switch vectors O Greco et al
In order to adapt our molecular switch system for efficient delivery to tumors in situ, nonreplicative adenovirus vectors have been produced and tested to assess both promoter inducibility and molecular switch functionality. To investigate the activity of the radiationinducible promoter, U87-MG cells were infected with adenovectors bearing HSVtk under control of either the E9 (AdE9tk) or the CMV IE (AdCMVtk) promoter. Transduced cultures were either irradiated or shamirradiated, in the presence or absence of GCV. Without stimulation, the AdE9tk vector was inactive, while, following irradiation, it mediated B55% GCV-mediated cell kill. As the 3 Gy radiation dose alone produced B25% cell kill, B30% of the AdE9tk cytotoxicity is attributable to radiation-mediated gene therapy, while the B85% cell kill produced by AdCMVtk was unaffected by radiation treatment. In a second study, to examine the functionality of the molecular switch in the adenovirus context, U87-MG cells were infected with AdCMVCre and AdCMVStoptk. When administered alone, the two viruses produced negligible cytotoxicity, when coinfected, B75% cell death was observed, demonstrating that the molecular switch system functions well using adenovirus vectors. Nonreplicative adenovirus vectors will provide safe delivery to the tumor site and the condition-specific promoters will ensure activation within the tumor only. In this instance, as infection of all tumor cells is unlikely, the HSVtk/GCV bystander effect will make a major contribution to therapeutic efficacy.
In conclusion, hypoxia-and radiation-activated molecular switch vectors represent a promising tool for targeted gene therapy of solid tumors. The development of the molecular switch system described here has the advantage of requiring the delivery of only a single vector to the tumor, for example in an adenovirus vector, and is therefore more applicable to clinical use than previous dual-vector schemes. We believe that the incorporation of this strategy into standard radiotherapy regimens will lead to significant increase in treatment efficacy for tumors sites where local control and refractive hypoxia are critical issues.
Materials and methods
Cell culture and transfection
Human MCF-7 mammary adenocarcinoma, U87-MG and U373-MG glioma cells (European Collection of Cell Cultures, Salisbury, UK) were maintained in RPMI medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin (Sigma Aldrich, St Louis, MO, USA), 2 mM L-glutamine (Invitrogen), in a humidified incubator at 371C in 5% O 2 :5% CO 2 :90% N 2 . Transfections were performed using TransIT (Mirus Corporation, Madison, WI, USA), according to the manufacturer's instructions. To obtain stably transfected lines, clones were selected over 2 weeks in complete medium containing the neomycin analogue G418 (Invitrogen) at 0.5 mg/ml active drug. Cells were routinely tested and found free of mycoplasma infection (PCR Mycoplasma Detection Set; Takara Bio Inc., Otsu, Japan).
Vector construction
The pE9CreStoptk switch plasmid was constructed via a multistage process. The BamHI, SgfI and NotI restriction sites in the vector pCIneo (Promega, Madison, WI, USA) were deleted by linearization, followed by creating blunt ends using the DNA Polymerase I Large Klenow fragment. The Cre coding sequence (CDS) was subcloned from pBS185 (Invitrogen) into the modified pCIneo digested with XhoI and MluI. The resultant Cre plasmid was digested with BamHI and SgfI, and a B100 bp region in the middle of the Cre CDS removed and reconstituted, using two complementary oligodeoxyribonucleotides (Cruachem, Glasgow, UK) that simultaneously deleted the BamHI and SgfI sites while producing codons that retain the native amino-acid sequence. The E9 CArG enhancer was inserted into the new Cre vector as described previously, 26 producing pE9Cre. Next, the 1.35 kbp BglII/BamHI fragment, containing the CMV IE promoter and the multiple cloning site, was isolated from the pCI plasmid (Promega) and cloned into the BamHI site of pE9Cre. Finally, the StopHSVtk cassette was excised from pStk 18 by EcoRI/NotI digestion and inserted into the pCI-derived polylinker to form pE9-CreStoptk. To obtain pEpoCreStoptk and pEpo/E9CreS-toptk (Figure 2 ), the promoter region in pE9CreStoptk was exchanged with those from the plasmids pEpoGFP and pEpo/E9GFP, 17 respectively, by digestion with EclHKI, followed by creating blunt ends with Klenow, and then digesting with I-PpoI. pEpotk and pEpo/E9tk were constructed by replacing the GFP gene and the puromycin resistance cassette in pEpoGFP and pEpo/ E9GFP 17 with the HSVtk gene and the neomycin resistance cassette from ptk, 18 by EcoRI/BamHI digestion. pEpo/E9CreStopGFP was obtained by replacing Stoptk with StopGFP in pEpo/E9CreStoptk. Enzymes (MBI Fermentas; Hanover, MD; New England Biolabs; Beverly, MA, USA) were used according to the manufacturer's instructions.
Cre recombinase reaction and PCR analysis
One unit of Cre (New England Biolabs) was incubated at 371C with 300 ng of purified target plasmid DNA and reaction buffer for 30 min. The purified DNA was linearized with NotI and used in PCR analysis. Two PCR primers were used, corresponding to opposing ends of the Stop sequence, and directed towards the terminal loxP sites. PCR reactions were carried out using Eppendorf Mastermix and 100 ng of each primer.
Hypoxic conditions
For experiments under hypoxic conditions, cultures were manipulated in a 371C anaerobic glove cabinet (PlasLabs, Lansing, MI, USA) with 5% CO 2 :5% H 2 :90% N 2 and a palladium catalyst. Anaerobic conditions were monitored with BR55 anaerobic indicators (Oxoid Ltd, Basingstoke, UK). The cells were plated in O 2 -impermeable dishes (Permanox, Nalge Nunc International, Rochester, NY, USA), transfected in air and subsequently incubated in air-tight Plexiglas boxes flushed with a humidified gas mixture with 5% CO 2 and balance N 2 . Plastics and fluids were preincubated in the cabinet for about 1 week prior to use, to remove residual oxygen.
Hypoxia-and radiation-activated switch vectors O Greco et al
